Pathogen: Influenza virus

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

MIViral

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

RESP-VIR

Italy
|
2025-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Hospital
  • Non-hospital health centre
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Rhinovirus
  • Parainfluenza Virus
  • Metapneumovirus

BUCOSS RSV 60+

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

PAPI Study

Germany
|
2021
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Human metapneumovirus

PANTHER

United Kingdom
|
2026
  • Adults (18-64 years)
  • General population
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Pharmacological intervention
  • Immunomodulator
  • Baricitinib
  • Statins
  • Simvastatin

EU-PROACT

France Norway Spain Belgium Italy United Kingdom Ireland Austria The Netherlands Switzerland
|
2025
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus

ECRAID-PRIME

Belgium France Germany Ireland Poland Spain United Kingdom Georgia
|
2024
  • Adults (18-64 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Pharmacological intervention
  • Nitric Oxide Nasal Spray

ECRAID-REMAP-CAP

Belgium Croatia Czech Republic Estonia France Germany Hungary Ireland Italy The Netherlands Portugal Serbia Slovenia Spain Switzerland United Kingdom
|
2018
  • Adults (18-64 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Pharmacological intervention
  • Immunomodulator
  • Corticosteroid
  • Baloxavir
  • Oseltamivir

ECRAID-EU-RECOVERY

France Italy The Netherlands Belgium Estonia Portugal Romania Spain Sweden
|
2020
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Children (1-11 years)
  • Adolescents (12-17 years)
  • Hospital
  • SARS-CoV-2
  • Influenza virus
  • Influenza A(H5N1) virus
  • Pharmacological intervention
  • Antivirals
  • Corticosteroid
  • Baloxavir
  • Oseltamivir

REACT

Spain Denmark South Africa
|
2022-2026
  • Adults (18-64 years)
  • Hospital
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Blood sample
  • PBMC
  • Serum
  • Whole blood
  • Plasma